The Impact of Prehospital Tranexamic Acid on Blood Coagulation in Trauma Patients by Stein, Philipp et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
The Impact of Prehospital Tranexamic Acid on Blood Coagulation in
Trauma Patients
Stein, Philipp; Studt, Jan-Dirk; Albrecht, Roland; Müller, Stefan; von Ow, Dieter; Fischer, Simon;
Seifert, Burkhardt; Mariotti, Sergio; Spahn, Donat R; Theusinger, Oliver M
Abstract: BACKGROUND: here is limited data on prehospital administration of tranexamic acid (TXA)
in civilian trauma. The aim of this study was to evaluate changes in coagulation after severe trauma
from on-scene to the hospital after TXA application in comparison to a previous study without TXA.
METHODS: he study protocol was registered at ClinicalTrials.gov (NCT02354885). A prospective, mul-
ticenter, observational study investigating coagulation status in 70 trauma patients receiving TXA (1
g intravenously) on-scene versus a control group of 38 patients previously published without TXA. To
account for potential differences in patient and trauma epidemiology, crystalloid and colloidal resuscita-
tion fluid, 2 propensity score matched groups (n = 24 per group) were created. Measurements included
ROTEM, standard coagulation tests and blood gas analyses on-scene and emergency department admis-
sion. Presented values are mean and [standard deviation], and difference in means and 95% confidence
intervals. RESULTS: atient epidemiology was not different between groups. Coagulation assays on-scene
were comparable between the TXA and C. Prehospital hyperfibrinolysis was blunted in all 4 patients
in the TXA group. Viscoelastic FIBTEM maximum clot firmness (MCF), representing functional fib-
rinogen levels, did not change from on-scene to the emergency department in the TXA group, whereas
MCF decreased -3.7 [1.8] mm in the control group. Decrease of MCF was significantly reduced in the
TXA group in EXTEM by 9.2 (7.2-11.2) mm (P < .001) and INTEM by 6.8 (4.7-9.0) mm (P < .001) in
favor of the TXA group. Production of fibrinogen fragments (represented by D-dimers) was significantly
lower in the TXA group compared to group C. CONCLUSIONS: arly prehospital administration of TXA
leads to clot stabilization and a reduction of fibrinolytic activity, causing a decrease in fibrin degradation
products buildup (D-dimer).
DOI: https://doi.org/10.1213/ANE.0000000000002708
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-143549
Journal Article
Published Version
Originally published at:
Stein, Philipp; Studt, Jan-Dirk; Albrecht, Roland; Müller, Stefan; von Ow, Dieter; Fischer, Simon; Seifert,
Burkhardt; Mariotti, Sergio; Spahn, Donat R; Theusinger, Oliver M (2018). The Impact of Prehospital
Tranexamic Acid on Blood Coagulation in Trauma Patients. Anesthesia and Analgesia, 126(2):522-529.
DOI: https://doi.org/10.1213/ANE.0000000000002708
Copyright © 2017 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
XXX 2017 • Volume XXX • Number XXX www.anesthesia-analgesia.org 1
DOI: 10.1213/ANE.0000000000002708
Exsanguination still remains the primary cause of early mortality in civilian trauma.1 Recent studies have shown that acute traumatic coagulopathy aggravate bleeding.
2–4 Early clot degradation by fibrinolysis was iden-
tified as being one of the key aspects in acute traumatic 
coagulopathy and massive bleeding.5 Several studies on 
the clinical use of the antifibrinolytic tranexamic acid (TXA) 
have been performed.6 To date, there is only 1 large ran-
domized controlled trial, the Clinical Randomisation of an 
Antifibrinolytic in Significant Haemorrhage 2 (CRASH-2), 
where the in-hospital administration of TXA in trauma vic-
tims has been investigated and a positive effect on mortal-
ity was found.7–9 Recently, the benefit of general in-hospital 
TXA administration to all trauma patients irrespective of 
the presence or absence of hyperfibrinolysis has been ques-
tioned.10,11 Nevertheless, the current European Trauma 
Treatment Guidelines recommend the early use of TXA in 
bleeding trauma patients.12 In addition, up to now, only few 
retrospective studies on the prehospital use of TXA exist13–15 
and the exact mechanism of action of early TXA administra-
tion in trauma patients is insufficiently known.
We thus performed the current prospective study in 
which trauma patients received 1g of TXA after the first 
blood sample was taken on-scene and coagulation was 
reassessed in the emergency department (ED) to determine 
the influence of TXA on the early evolution of coagulation 
KEY POINTS
• Question: Are there changes in coagulation after severe trauma from on-scene to the hospital 
after tranexamic acid (TXA) application in comparison to a previous study without TXA?
• Findings: Early prehospital administration of TXA leads to clot stabilization and a reduction of 
fibrinolytic activity, causing a decrease in fibrin degradation products buildup (D-dimer).
• Meaning: Emergency medical services should use TXA in the preclinical setting to improve 
coagulation in severe trauma patients.
BACKGROUND: There is limited data on prehospital administration of tranexamic acid (TXA) in 
civilian trauma. The aim of this study was to evaluate changes in coagulation after severe trauma 
from on-scene to the hospital after TXA application in comparison to a previous study without TXA.
METHODS: The study protocol was registered at ClinicalTrials.gov (NCT02354885). A prospec-
tive, multicenter, observational study investigating coagulation status in 70 trauma patients 
receiving TXA (1 g intravenously) on-scene versus a control group of 38 patients previously 
published without TXA. To account for potential differences in patient and trauma epidemiology, 
crystalloid and colloidal resuscitation fluid, 2 propensity score matched groups (n = 24 per 
group) were created. Measurements included ROTEM, standard coagulation tests and blood 
gas analyses on-scene and emergency department admission. Presented values are mean and 
[standard deviation], and difference in means and 95% confidence intervals.
RESULTS: Patient epidemiology was not different between groups. Coagulation assays on-scene 
were comparable between the TXA and C. Prehospital hyperfibrinolysis was blunted in all 4 
patients in the TXA group. Viscoelastic FIBTEM maximum clot firmness (MCF), representing 
functional fibrinogen levels, did not change from on-scene to the emergency department in the 
TXA group, whereas MCF decreased −3.7 [1.8] mm in the control group. Decrease of MCF was 
significantly reduced in the TXA group in EXTEM by 9.2 (7.2–11.2) mm (P < .001) and INTEM 
by 6.8 (4.7–9.0) mm (P < .001) in favor of the TXA group. Production of fibrinogen fragments 
(represented by D-dimers) was significantly lower in the TXA group compared to group C.
CONCLUSIONS: Early prehospital administration of TXA leads to clot stabilization and a reduc-
tion of fibrinolytic activity, causing a decrease in fibrin degradation products buildup (D-dimer). 
(Anesth Analg 2017;XXX:00–00)
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after trauma; the hypothesis being that clot degradation is 
stopped by the early administration of TXA.
METHODS
The study was approved by the local ethics committee 
(Kantonale Ethikkommission Zurich, Switzerland, study 
number KEK-ZH 2014-0069) including the fact that subjects 
were exempted from providing written consent because 
the first blood sample was drawn under conditions in 
which patients could not give informed consent.16 Once the 
patients were medically stabilized, they were approached 
to provide a delayed informed consent. In case of death, the 
patients’ relatives were contacted. Without informed con-
sent, all samples and data were discarded. The study proto-
col was registered at ClinicalTrials.gov (NCT02354885).
This multicenter prospective observational study was 
conducted in 3 level-1 trauma centers in Switzerland 
(University Hospital Zurich, Cantonal Hospitals of 
Lucerne, and Saint Gallen) in collaboration with the emer-
gency medical service (EMS) of the city of Zurich (Schutz 
und Rettung Zurich, Zurich, Switzerland) and the helicop-
ter EMS Rega (Swiss Air-Ambulance, Rettungsflugwacht, 
Garde Aérienne, Zurich Airport, Zurich, Switzerland).
The enrollment for this study was conducted between 
December 2014 and March 2016. Samples of the control 
group (no prehospital administration of TXA) were col-
lected between April 2009 and October 2012 and previously 
published by Theusinger et al.17
Study eligibility was given for patients aged ≥18 years 
with severe trauma or traumatic brain injury with a national 
advisory committee for aeronautics score ≥3 receiving 
prehospital TXA after blood sampling. The national advi-
sory committee for aeronautics score is only used for the 
prehospital qualification of patients and does not corre-
late well with the post hoc calculated injury severity score 
(ISS) which is used as a standard for injury classification in 
trauma patients. After recruiting the necessary number of 
patients with an ISS ≥16 (as indicated by sample size calcula-
tion), patient enrollment was stopped. For the final analysis, 
patients with ISS ≥9 were included. Patients were excluded 
if they were pregnant, <18 years of age, unable to speak 1 of 
the national languages, or if they denied informed consent 
(Figure 1).
The sample collection of the control group was previously 
published and described in detail by Theusinger et al.17 In 
the TXA group, the initial medical treatment of patients was 
not delayed for study purposes. The second intravenous 
line, as recommended by Pre-Hospital Trauma Life Support 
(PHTLS), 8th edition, for severely traumatized patients, 
was used to collect the blood samples on-scene: 9 mL of 
citrated blood (S-Monovette; Sarstedt AG&Co, Nürnbrecht, 
Germany, containing 1 mL 3.2% trisodium citrate) and 1.7 
mL in a blood gas analysis syringe (SafePICO aspirator, 
Radiometer Medical, Bronshoj, Denmark, containing 80 IU 
heparin). Thereafter, 1 g of TXA (MEDA Pharma GmbH, 
Wangen-Bruttisellen, Switzerland) was given intravenously. 
A second identical set of blood samples was drawn when 
the patient arrived in the ED of one of the level-1 trauma 
centers mentioned above.
Laboratory data acquisition consisted of blood gas sam-
ples (on-scene and ED), which were immediately analyzed 
by ABL 800 (Radiometer Medical, Bronshoj, Denmark) and 
pH, hematocrit, hemoglobin, lactate, base excess, anion 
gap, and bicarbonate were measured. Coagulation values 
included data from whole blood ROTEM (TEM International 
GmbH, Munich, Germany) measurements were performed 
within 120 minutes of blood sampling.18 INTEM (ellagic acid 
activated intrinsic pathway), EXTEM (tissue factor activated 
extrinsic pathway), FIBTEM (containing platelet inhibitor 
cytochalasin D, evaluating the contribution of fibrinogen to 
clot formation), and APTEM (containing aprotinin to inhibit 
plasmin to evaluate fibrinolysis) tests were performed and 
maximal clot firmness (MCF) and maximal lysis (ML) were 
determined. The remaining citrated plasma was stored at 
Figure 1. Flowchart of study inclusion 
criteria. ISS indicates injury severity 
score; NACA, national advisory com-
mittee for aeronautics; TXA, tranexamic 
acid.
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−80°C and collectively analyzed in the quality controlled 
International Organization for Standardization (ISO) 17025 
accredited central hematology laboratory of the University 
Hospital Zurich after the completion of the study. Assessment 
of international normalized ratio (INR) was determined by the 
Behring Coagulation System (BCS) XP (Siemens Healthcare 
Diagnostics GmbH, Eschborn, Germany) using the Innovin 
test. Fibrinogen (Clauss method) was measured by BCS XP 
using Multifibrin U. FXIII activity was determined by BCS 
XP (Siemens Healthcare Diagnostics GmbH). Protein C activ-
ity was measured using the protein C chromo on BCS XP. 
D-Dimers were determined using the mini VIDAS D-Dimer 
Exclusion (bioMerieux, Lyon, France) test. Factor V activity 
was determined by BCS XP (Factor V-Dade Innovin, Siemens 
Healthcare Diagnostics GmbH).
Demographic data included type of trauma. ISS and ana-
tomical-based abbreviated injury scores were documented 
or calculated respectively by medical encoders responsible 
for the annual report for the TraumaRegister database of the 
German Society of Trauma Surgery. Patient demographics 
(sex, age), vital parameters (heart rate, systolic blood pres-
sure) at the scene and in the ED, type and quantity of resusci-
tation fluid were documented. Crystalloid solution used by 
EMS and helicopter emergency medical service (HEMS) was 
balanced lactated solution (Ringerfundin, B Braun Medical, 
Sempach, Switzerland). In the TXA group, 1 patient received 
colloid in the form of balanced gelatin (Physiogel balanced, 
B Braun Medical). In the control group, the used colloid was 
6% hydroxyethyl starch (Tetraspan HES 130/0.42, B Braun).
Primary outcome was the impact of prehospital TXA on 
the availability of functional fibrinogen and clot stability 
(D-dimer production and maximum lysis indices).
Statistical Analyses
The data were entered into a spreadsheet (Microsoft Excel: 
Mac 2011, version 13.5.3, Microsoft Corporation, Redmond, 
WA). Statistical data were analyzed with IBM SPSS Statistics 
(version 22, IBM, Armonk, NY).
For the primary analysis, 2 propensity score matched 
groups (n = 24 per group) were computed using a nonparsi-
monious logistic regression for TXA application to account 
for potential differences in patient epidemiology, crystal-
loid and colloidal resuscitation fluid. Explanatory variables 
were patient age, sex, body mass index, ISS, abbreviated 
injury score ≥3 (head, thorax, abdomen, extremities), iso-
lated traumatic brain injury, systolic blood pressure, heart 
rate, and crystalloid and colloidal fluid. Propensity score 
matching was performed on the logit scale with a caliper of 
0.2 standard deviations of the logit of the propensity score. 
Standardized difference was calculated for the explanatory 
variables to assess the balance on base line characteristics 
after propensity score matching. Continuous data were pre-
sented as mean and standard deviation. The primary out-
come variables related to clot degradation (difference from 
scene to ED) were calculated. Difference in means and 95% 
confidence intervals between the groups were calculated. 
The Mann-Whitney U test was used to compare continu-
ous data between the groups and to calculate the P values. 
The Mann-Whitney U test was used throughout the manu-
script in a unified way because of its high level of efficacy 
independent from data distribution. The χ2 and Fisher exact 
test were used to assess the differences in categorical demo-
graphic patient data. P values ≤.01 were considered statis-
tically significant. This conservative value was chosen to 
reduce the probability of false positive findings.
Sample Size Calculation. Based on the available data of 
the control group, a sample size calculation was performed 
to establish the study plan. This calculation intended to 
identify the required amount of severely injured patients 
(ISS ≥16) in the TXA group to detect a significant relative 
reduction by 50% of FIBTEM MCF decrease from the scene 
to the hospital compared to the control group. 
RESULTS
Baseline Characteristics
A total of 108 patients with ISS ≥9 were included to the 
study. The TXA group consisted of 70 patients and the con-
trol group (C) of 38 patients. To account for potential differ-
ences in patient epidemiology, vital parameters, severity of 
trauma, body trauma region, crystalloid and colloidal resus-
citation fluid, 2 propensity score matched groups (n = 24 per 
group) were created. The absolute standardized difference 
after matching was <0.20 for all explanatory variables, which 
confirms a valid matching (Table 1). All data presented in the 
manuscript are derived from the propensity score matched 
groups. Data including all 108 patients (unmatched) are pro-
vided in Supplemental Digital Contents 1–3, Table 1, http://
links.lww.com/AA/C151, Table 2, http://links.lww.com/
AA/C152, Table 3, http://links.lww.com/AA/C153.
Baseline (on-scene) blood gas values and hemoglobin 
value were not different between both groups (Table  2). 
ROTEM and coagulation assays on-scene were largely com-
parable between the TXA and C. However, on-scene ML of 
EXTEM and INTEM were significantly higher in the TXA 
group and factor V activity was significantly lower in the 
TXA group (Table 2).
Change of ROTEM Maximum Clot Firmness From 
On-Scene to ED
FIBTEM maximum clot firmness (MCF), representing func-
tional fibrinogen polymerization, did not change from on-
scene to the ED in the TXA group, whereas FIBTEM MCF 
decreased −3.7 [1.8] mm without TXA application in group 
C, resulting in a significant difference in means between the 
groups of 3.5 (2.1–4.8) mm (P < .001, Table 3). FIBTEM MCF 
difference in regard to ISS is shown in Figure 2A.
EXTEM and INTEM MCF decrease from on-scene to the 
ED was significantly reduced in the TXA group compared 
to the control group: EXTEM by 9.2 (7.2–11.2) mm (P < .001) 
and INTEM by 6.8 (4.7–9.0) mm (P < .001) in favor of the 
TXA group (Table 3).
Fibrinolysis
On-scene hyperfibrinolysis (EXTEM ML >15%) was present 
in 4 patients in the TXA group and 2 patients in the control 
group. Hyperfibrinolysis was blunted in all 4 patients in the 
TXA group. Reduction of ML was higher in the TXA group 
in EXTEM (difference in means 12% (1–24); P < .001) and 
INTEM (difference in means 9% (−3 to 22), P < .001) com-
pared to group C (Table 3).
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Changes in Hematology and Blood Gas Analyses 
From On-Scene to ED
Hematology and blood gas analyses differences from on-
scene to ED were not significantly different between group 
TXA and C (Table 3).
Change of Coagulation Assays From  
On-Scene to ED
On-scene fibrinogen fragments (represented by D-dimer 
levels) increase with injury severity (Figure 2B). Production 
of fibrinogen fragments (represented by D-dimers) was 
significantly lower in the TXA group compared to group C 
(P = .002, Table 3, Figure 3).
The decrease of fibrinogen plasma level (Clauss 
method) from on-scene to ED was not different between 
the groups. On-scene to ED changes of coagulation factor 
V and XIII activity, protein C activity, Quick’s value, and 
INR were not different between TXA and control group 
(Table 3).
DISCUSSION
The main findings of this study are (1) FIBTEM, EXTEM, 
and INTEM MCF decrease from on-scene to the ED was sig-
nificantly reduced in the TXA group compared to the con-
trol group, (2) fibrinolysis is inhibited by prehospital TXA 
application, (3) on-scene fibrinogen fragments increase with 
Table 2. On-Scene and Emergency Department Laboratory and ROTEM Values
 
On-Scene Values ED Values
TXA, n = 24 C, n = 24  TXA, n = 24 C, n = 24  
Mean [SD] Mean [SD] P Value Mean [SD] Mean [SD] P Value
pH 7.33 [0.08] 7.33 [0.05] .96 7.35 [0.11] 7.32 [0.07] .36
Standard bicarbonate (mmol/L) 23.2 [2.8] 22.5 [3.5] .53 21.8 [2.7] 22.2 [3.1] .57
Base excess −2.3 [2.9] −3.0 [3.5] .43 −3.1 [3.0] −3.3 [3.3] .89
Anion gap (mmol/L) 10.9 [3.9] 8.1 [4.1] .04 8.7 [3.9] 7.2 [3.2] .19
Hemoglobin (g/L) 151 [20] 143 [18] .21 126 [24] 122 [26] .53
Lactate (mmol/L) 3.3 [1.9] 2.9 [1.6] .27 2.1 [1.5] 2.3 [1.8] .38
EXTEM MCF (mm) 60 [7] 58 [8] .73 61 [6] 50 [8] <.001
EXTEM ML (%) 17 [26] 6 [7] <.001 5 [3] 6 [6] .54
INTEM MCF (mm) 58 [7] 57 [11] .56 57 [6] 50 [11] .004
INTEM ML (%) 18 [26] 8 [16] <.001 7 [3] 6 [5] .07
FIBTEM MCF (mm) 14 [5] 15 [4] .46 14 [5] 11 [3.5] 010
FIBTEM ML (%) 10 [28] 6 [20] .66 6 [13] 5 [6] .23
Quick’s value (%) 82 [21] 83 [17] .89 77 [21] 85 [14] .19
INR 1.2 [0.2] 1.1 [0.1] .59 1.2 [0.2] 1.1 [0.1] .14
Fibrinogen (g/L) 2.4 [1.1] 2.5 [0.7] .34 1.9 [0.9] 2.1 [0.5] .11
Factor XIII activity (%) 117 [24] 105 [24] .10 100 [29] 88 [25] .04
Factor V activity (%) 84 [25] 108 [36] .005 67 [24] 93 [23] .001
D-Dimers (mg/dL) 6.3 [4.8] 4.9 [4.5] .33 6.3 [4.9] 8.8 [7.6] .41
Protein C activity (%) 95 [20] 94 [21] .73 84 [20] 81 [21] .45
Mean and [SD] of the values (propensity score matched group) on-scene and in the emergency department are summarized. The P value (Mann-Whitney U test) 
was calculated between the groups TXA and C. P values ≤.01 were considered statistically significant and are printed in boldface.
Abbreviations: CFT, clot formation time; CT, clotting time; ED, emergency department; INR, international normalized ratio; MCF, maximum clot firmness; ML, 
maximum lysis; SD, standard deviation, TXA, tranexamic acid.
Table 1. Demographic Data of the Tranexamic Acid and Control Group
 Demographic Data
 Propensity Score Matched Group   
 (TXA, n = 24) (C, n = 24)   
 n (%)/Mean [SD] n (%)/Mean [SD] Standardized Difference P Value
Age (y) 45.4 [18.9] 47.5 [21.0] 0.102 .79
Patient sex: male 20 (83%) 20 (83%) 0 >.99
BMI (kg/m2) 25.2 [2.9] 24.8 [3.6] 0.117 .40
ISS 25 [15] 26 [17] 0.096 .79
AIS (head) ≥3 14 (58%) 15 (63%) 0.085 >.99
AIS (thorax) ≥3 8 (33%) 9 (38%) 0.087 >.99
AIS (abdomen) ≥3 3 (13%) 3 (13%) 0 >.99
AIS (extremities) ≥3 8 (33%) 8 (33%) 0 >.99
Isolated TBI 7 (29%) 6 (25%) 0.094 >.99
Systolic BP (mm Hg) 135 [29] 129 [28] −0.154 .16
Heart rate (1/min) 85 [14] 86 [23] 0.054 .76
Crystalloid fluid (mL) 526 [366] 506 [327] −0.058 .96
Colloidal fluid (mL) 21 [102] 45 [132] 0.194 .32
Baseline patient and trauma epidemiology of the propensity score matched groups. The P value (Mann-Whitney U test for continuous data, χ2 test, Fisher exact 
test for categorical data) was calculated between the 2 groups (TXA and C). Values are expressed as mean and [SD] or number (%). Standardized difference = 
difference in means or proportions divided by pooled SD; imbalance defined as absolute value >0.20 (small effect size) = no imbalance in the matched groups.
Abbreviations: AIS, abbreviated injury scale; BMI, body mass index; BP, blood pressure; ISS, injury severity score; SD, standard deviation; TBI, traumatic brain 
injury; TXA, tranexamic acid.
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injury severity, and (4) D-dimer production is significantly 
lower in the TXA group.
Since the CRASH-2 study,8,9 several recommendations 
regarding the early use of TXA in trauma patients have been 
made including the latest update of the European Trauma 
Guidelines.12 Only little data are available on changes of 
coagulation factors and rotational thromboelastometry after 
the administration of TXA application on-scene of trauma.19 
The study by Theusinger et al17 regarding changes of coagu-
lation and ROTEM in trauma patients between on-scene and 
the ED which served as control group showed a clear reduc-
tion of the MCF in FIBTEM, EXTEM, and INTEM as well as 
an increase in lysis parameters which was a clear indicator 
that coagulation factors are being used and that fibrinoly-
sis was ongoing. The administration of TXA resulted in a 
reduced decrease of MCF in FIBTEM, EXTEM, and INTEM 
between on-scene and the ED and clot lysis was inhibited 
when patients arrived in the ED. Nevertheless, due to the 
ongoing blood loss, a reduction of coagulation factors could 
still be observed. Another argument regarding the more 
Table 3. Changes of Laboratory and ROTEM Values Between On-Scene and the ED
 
Changes From On-Scene to ED 
Admission
Difference Between  
TXA and C
C, n = 24 TXA, n = 24 Difference in Means  
(95% CI)
P  
ValueMean [SD] Mean [SD]
pH 0.00 [0.07] 0.02 [0.09] −0.02 (−0.07 to 0.03) .43
Standard bicarbonate (mmol/L) −0.3 [2.6] −1.4 [2.8] 1.1 (−0.5 to 2.6) .21
Base excess −0.3 [2.3] −0.8 [2.1] 0.5 (−0.8 to 1.8) .90
Anion gap (mmol/L) −0.9 [3.1] −2.4 [3.1] 1.5 (−0.3 to 3.3) .13
Hemoglobin (g/L) −21 [27] −25 [19] 4 (−10 to 18) .28
Lactate (mmol/L) −0.6 [1.3] −1.2 [1.1] 0.6 (−0.1 to 1.3) .03
EXTEM MCF (mm) −8.2 [4.1] 1.0 [2.5] −9.2 (−11.2 to −7.2) <.001
EXTEM ML (%) 0 [4] −12 [27] 12 (1–24) <.001
INTEM MCF (mm) −7.7 [4.5] −0.8 [2.7] −6.8 (−9.0 to −4.7) <.001
INTEM ML (%) −2 [16] −11 [20] 9 (−3 to 22) <.001
FIBTEM MCF (mm) −3.7 [1.8] −0.2 [2.8] −3.5 (−4.8 to −2.1) <.001
FIBTEM ML (%) −1 [22] −4 [31] 3 (−12 to 19) .08
Quick’s value (%) 2 [16] −6 [17] 7 (−2 to 17) .14
INR 0.0 [0.1] 0.0 [0.2] −0.1 (−0.2 to 0.0) .26
Fibrinogen (g/L) −0.4 [0.5] −0.5 [0.5] 0.1 (−0.2 to 0.4) .41
Factor XIII activity (%) −18 [18] −17 [21] −1 (−12 to 11) .85
Factor V activity (%) −15 [23] −18 [17] 3 (−9 to 14) .51
D-dimers (mg/dL) 3.9 [5.4] 0.1 [2.2] 3.9 (1.5 to 6.3) .002
Protein C activity (%) −13 [18] −11 [16] −2 (−12 to 8) .58
Differences (propensity score matched groups) between on-scene and ED values were calculated and summarized as mean and [SD] for both groups (TXA and 
C). Difference in means, (95% CI), and P value (Mann-Whitney U test) of the on-scene to ED changes between the groups TXA and C were calculated. P values 
≤.01 were considered statistically significant.
Abbreviations: C, control; CI, confidence interval; ED, emergency department; INR, international normalized ratio; MCF, maximum clot firmness, ML, maximum 
lysis, SD, standard deviation; TXA, tranexamic acid.
Figure 2.  A, Changes of maximum clot firmness (MCF) FIBTEM between on-scene and the emergency department regarding injury severity 
score. FIBTEM MCF differences between on-scene and the emergency department (ED) between the groups tranexamic acid (TXA) and control 
(C) are displayed in regard to ISS. B, On-scene D-dimers in regard to ISS. On-scene fibrinogen fragments (represented by D-dimer levels) 
increase with injury severity.
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stable MCF in the TXA group is that the use of colloids in 
the prehospital setting of trauma patients and in all other 
patients was abandoned since 2014 as clear evidence was 
published regarding the clot impairment by their use.20 The 
propensity score groups were not only matched for patient 
demographics but also for crystalloid and colloidal resusci-
tation fluid.
D-Dimers, being a degradation product of 
fibrinogen/fibrin, is one of the few readily available 
standard laboratory tests as an indirect indicator of 
fibrinolysis/hyperfibrinolysis. The fact that the applica-
tion of TXA leads to a stagnation of the D-dimer produc-
tion between on-scene and the ED is clear evidence that 
degradation of the clot was stopped. On the other hand, we 
were able to show that on-scene fibrinogen fragments (rep-
resented by D-dimer levels) increase with injury severity 
and therefore they provide indirect information regarding 
the severity of trauma.21
Previous studies have indicated that elevated D-dimer 
levels are also associated with a poor outcome,22–25 as well as 
the severity of tissue damage which is confirmed by our ISS 
correlation.26–28 Gando et al29 reported that high D-dimer lev-
els on arrival at the ED indicated hyperfibrinolysis and pre-
dicted massive bleeding and death.22–24 On the other hand, 
in an actual study by Hayakawa et al21 have shown that high 
D-dimer levels on arrival at the ED are only a strong predic-
tor of early death or a requirement for massive transfusion 
in severe trauma patients, regardless of fibrinogen levels, 
which may indicate hyperfibrinolytic status. The study pre-
sented in this manuscript showed that also patients with 
low ISSs9–15 experience a decrease in functional fibrinogen 
levels from the injury scene until hospital admission which 
is blunted by TXA application (Figure 2A). As the inclusion 
criteria were along the lines with the CRASH-2 judged clini-
cally (patients with trauma at risk for significant bleeding), 
also patients without numerical evidence of hemorrhagic 
shock might be prone to clot lysis due to released tissue 
plasminogen activator.
The evidence for early untargeted administration of 
TXA has been recently questioned by different publica-
tions.6,10,11 A recent civilian study from the United Kingdom 
demonstrated that only severely injured patients in shock 
had a survival benefit with TXA, with a reduction in mor-
tality from 15% to 11%.30 Moore et al11 were able to show 
in a study with 2540 patients that different phenotypes of 
fibrinolysis exist. The fibrinolysis shutdown phenotype was 
present in 46% of the patients. The mortality in that group 
was higher than in the group of patients with physiologic 
fibrinolysis. Therefore, in case of fibrinolysis shutdown, the 
administration of TXA might be questionable. In a study by 
Harvin et al,10 TXA was administered in the ED, only after 
hyperfibrinolysis was proven by point of care devices. Of 
the 1000 patients included in their study, only 10% received 
TXA without effect on mortality. Based on our data, we dis-
agree with the proposal that TXA should be administered 
only in the ED after hyperfibrinolysis has been proven, as 
we have clear indications that even in patients with a low 
ISS value, the production of D-dimers is stopped and clot 
firmness is stabilized which may represent be a benefit for 
patients. For the moment being, no point of care device 
exists which could be used to quickly guide the administra-
tion of TXA in the prehospital setting. We thus consider the 
“blind” TXA administration in severe trauma in the prehos-
pital setting reasonable.
Limitations of this study need to be mentioned. The 
sample size was relatively small. Blood loss was neither 
calculated nor estimated because the data were not avail-
able for the days after the trauma. For ethical reasons, blood 
samples on-scene and the ED were always performed with-
out disturbing life-sustaining treatment. This implicates 
that it might be possible that patients received a first dose 
of volume replacement before the first blood sample on-
scene was drawn. Samples for blood gas analysis and the 
blood samples for ROTEM and laboratory analyses were 
drawn from a second venous access site and not cooled on 
ice during transportation to the ED. Several studies have 
Figure 3. D-Dimers difference (on-scene to 
emergency department) between the groups 
(tranexamic acid [TXA] and control [C]). D-Dimers 
increase from on-scene to the emergency depart-
ment was significantly lower in the TXA group 
compared to group C (P = .002, Mann-Whitney U 
test). P values ≤.01 were considered statistically 
significant.
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demonstrated that blood samples remain stable over a long 
period of time at 21°C, so we do not believe these values dis-
tort our analysis.18,31,32 To account for differences in patient 
epidemiology and treatment differences in regard to resus-
citation fluids, we created propensity matched groups to 
correct for these confounders.
In conclusion, the early administration of TXA in the 
prehospital setting leads to a stabilization of the clot in 
ROTEM, functional fibrinogen availability, and a reduction 
of fibrinolytic activity represented by a lower increase of 
D-dimer levels. Furthermore, on-scene D-dimers increase 
with the ISS. More studies are needed to clearly evaluate 
the benefit of early TXA administration as different results 
have actually been published. E
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